Identifying Molecular Drivers of Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02470715|
Recruitment Status : Completed
First Posted : June 12, 2015
Last Update Posted : May 25, 2018
|Condition or disease||Intervention/treatment|
|Cancer Tumor Advanced Cancer||Genetic: Molecular profile|
|Study Type :||Observational|
|Actual Enrollment :||579 participants|
|Official Title:||Identifying Molecular Drivers of Cancer|
|Actual Study Start Date :||April 2014|
|Actual Primary Completion Date :||May 22, 2018|
|Actual Study Completion Date :||May 22, 2018|
Molecular profiled group receiving treatment based on genetics
Genetic: Molecular profile
Patients and their treating physician will obtain the patient's genetic risk assessment
Other Name: Genomic targeting
- Genetic profiling [ Time Frame: Up to 15 years ]To determine genetic changes associated with the development and growth of human disease. This should lead to better ways to detect, prevent, and treat a wide variety of human health conditions, including cancer.
Biospecimen Retention: Samples With DNA
Participants will have up to 3 blood tubes (about 30 ml) drawn under the condition that protocol criteria for blood sampling is met. Blood samples may be collected each time a participant undergoes a provider-ordered blood draw. Urine samples may also be collected approximately every 4-6 weeks.
Participants may be asked to provide approximately 60-120 ml of first-morning-void urine. Tissue from a standard care surgical procedure or biopsy may be obtained. Additional core biopsies (for research) or excess surgical waste will be collected during each biopsy procedure when appropriate and will be processed and stored.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02470715
|United States, South Dakota|
|Avera Cancer Institute|
|Sioux Falls, South Dakota, United States, 57105|
|Principal Investigator:||Brian Leyland-Jones||Avera McKennan Hospital & University Health Center|